ARKG ETF Rips 10.32% to a Record $47.67 as the First mRNA Cancer Vaccine Clears Phase 3

The ARK Genomic Revolution ETF closed Wednesday at $47.67 against a previous close of $43.21, a 10.32% single-session gain that marked the fund's strongest day in more than a year and took it to a record. The intraday range ran $45.17 to $47.70, and that $47.70 print is now the top of the 52-week range.

The bottom of that range is $23.43. The fund has slightly more than doubled inside twelve months.

Premarket on the day had marked $45.24 and the after-hours print was $47.60, which tells you the move held into the close rather than fading — the signature of institutional participation rather than a retail spike.

The catalyst arrived before the open. Moderna and Merck announced that intismeran autogene, their personalized mRNA cancer therapy, succeeded in a Phase 3 melanoma trial. Moderna rose 177% to $174.38 in its best session ever, taking its market capitalization from $25 billion to $69 billion. Merck gained roughly 13% to a record high, its best day since 2009.

The read-through hit every fund with genomics exposure. The iShares Genomics Immunology and Healthcare ETF jumped 13% for its best day on record. The SPDR S&P Biotech ETF gained between 4.3% and 6% depending on the measurement window, its strongest session in nearly five months, and closed at an all-time high. The iShares Biotechnology ETF added 5.3% to 6.58%, also a record. The Nasdaq Biotechnology Index climbed more than 6% to a record, and the S&P 500 healthcare sector posted its best day since April 2025.

At least 33 stocks from the healthcare, biotech and genomics complex reached new one-year highs in a single session.

Biotech reached its highest level since the height of the pandemic.

ARKG's 10% move was smaller than IDNA's 13% and larger than XBI's, which is exactly what its holdings composition predicts — the fund owns the sequencing and diagnostics infrastructure rather than the mRNA developers themselves.

The fund charges 0.75%, holds 33 to 34 positions, and was launched on October 31, 2014.

At $47.67 it is up 64% year-to-date and 90% over twelve months. There is no resistance above the current price because the fund has never traded higher.

The Trial That Repriced The Entire Complex

The specifics of what happened Wednesday matter because the durability of this move depends on them.

Moderna and Merck reported positive Phase 3 results from the INTerpath-001 trial. The study tested intismeran autogene — also known as mRNA-4157 — given alongside Merck's Keytruda against Keytruda alone in more than 1,100 high-risk melanoma patients whose tumors had already been surgically removed. The combination met its primary endpoint on recurrence-free survival and a key secondary endpoint on distant metastasis-free survival.

Patients on the combination went meaningfully longer without their cancer returning or spreading. That validates years of Phase 2 signals previously reported and makes this the first mRNA-based individualized neoantigen therapy to succeed in a registrational trial.

The mechanism is what generalizes. A patient's tumor is sequenced, the unique mutational signature is identified, and a bespoke mRNA construct is manufactured to train the immune system against those specific neoantigens. Every step of that process requires genomics infrastructure — sequencing instruments, synthetic DNA, bioinformatics, diagnostics.

That is precisely what ARKG owns.

The commercial estimates that followed were substantial. One firm raised its assumed probability of melanoma approval to 100% from 60% and lifted the lung cancer figure to 60% from 40%, expecting a potentially rapid approval in the first half of 2027 once data are submitted. Another put the adjuvant melanoma opportunity alone above $2 billion. A third cautioned that Moderna's valuation already reflected more than $20 billion in risk-adjusted peak sales — approaching Keytruda's blockbuster scale on an unadjusted basis.

The sober framing is worth carrying. This is a treatment vaccine, not a prophylactic one — it is used only in patients who already have cancer, and it is applied alongside an existing therapy. The result does not make personalized cancer vaccines a commercial certainty. Detailed clinical data, regulatory review, manufacturing economics and results across additional tumor types all still matter.

Manufacturing is the underappreciated constraint. Producing a bespoke therapeutic for each patient at commercial scale is an industrial problem nobody has solved.

For a fund holding sequencing and synthesis companies, that constraint is the opportunity.

Tempus AI At 7.09% Of The Fund Ripped 23.91%

The single holding that best explains why ARKG moved 10% rather than 4% is its third-largest position.

Tempus AI represents 7.09% of the fund. The stock moved 23.91% on August 19, opening at $49.36 and trading to $61.16.

The reason is a deal announced a month earlier that suddenly looked prescient. On July 20, Tempus agreed to acquire Personalis for $1.5 billion in a 100% stock transaction with an option to elect cash for up to half the consideration. Personalis had reported just $22.36 million in second-quarter revenue, which made the price look aggressive at the time.

Personalis makes NeXT Personal, an ultrasensitive minimal residual disease test that detects trace cancer DNA in blood. That same technology underpins the Moderna-Merck personalized mRNA neoantigen vaccine.

One month after the deal, the therapy it enables passed Phase 3. The market has been calling it the genomics purchase of the year.

The company's own results reinforced it. Tempus reported second-quarter revenue of $382.5 million, up 22% year-over-year, alongside its first-ever quarterly net profit. Management raised full-year 2026 revenue guidance to between $1.595 billion and $1.605 billion with adjusted EBITDA expected near $65 million. Data licensing grew 36% year-over-year on deals with major pharmaceutical names including Merck and Gilead.

Two earlier catalysts had been building. On August 4 a peer-reviewed study in Nature Medicine validated the accuracy of the company's PRISM2 platform for cancer diagnosis and outcome prediction. On August 6 a partnership with CellCarta made Tempus a commercial lab partner in an oncology diagnostics network.

Heavy short interest amplified Wednesday's move.

Personalis itself traded at $15.71, with its deal price now fixed by the merger terms.

For ARKG, a 23.91% move in a 7.09% position contributes roughly 1.7 percentage points of the fund's 10.32% gain on its own. The remainder came from the rest of the genomics complex repricing in sympathy.

That is what concentrated active management does in both directions.

What ARKG Actually Owns

The portfolio is the product, and it is unusually concentrated for an exchange-traded fund.

ARKG holds 33 to 34 individual positions with the top ten accounting for roughly 61.23% of assets. The largest holdings are 10x Genomics at 10.03%, Twist Bioscience at 9.19%, Tempus AI at 7.09%, CRISPR Therapeutics at 6.17% and Absci at 5.46%.

Sector exposure runs 98.4% health care with 90.8% of assets in the United States. Within health care, biotechnology accounts for roughly 70% to 75% of the portfolio and life sciences tools and services for 15% to 20%.

That composition explains the fund's behaviour Wednesday. It does not own Moderna. It owns the infrastructure layer that a personalized cancer vaccine requires: 10x Genomics for single-cell and spatial analysis, Twist Bioscience for synthetic DNA, Tempus for the diagnostic and data platform, CRISPR Therapeutics for gene editing, Absci for AI-driven drug design.

If mRNA moves successfully from infectious disease into individualized oncology, sequencing, genomics, diagnostics, immunology and drug discovery all become part of the same ecosystem. That is the thesis this fund was built on, and Wednesday was the first Phase 3 validation of it.

The mandate itself is broader than the current portfolio suggests. ARKG seeks long-term capital growth by investing at least 80% of assets in domestic and foreign equities across health care, information technology, materials, energy and consumer discretionary that are relevant to the genomics theme. In practice, the fund concentrates in health care and biotechnology.

The risk disclosures name the exposures directly: equity securities risk, foreign securities risk, health care sector risk including government regulation and reimbursement restrictions, and biotechnology company risk — where valuation is often based largely on the potential or actual performance of a limited number of products.

That last one is the honest description of what this fund owns. These are companies whose worth is a probability-weighted bet on clinical outcomes.

Active management means holdings can change within days when the research team shifts conviction or a position grows beyond target weight.

There is also overlap risk. ARKG and ARKK both hold CRISPR Therapeutics and Tempus AI, which means owning both doubles exposure rather than diversifying it.

The Thursday Give-Back And What It Proved

The session after a 177% move in a single name is the one that tests whether a repricing is real.

Moderna fell 18% to $142.70 in Thursday midday trading, and closed down 22.10% — unwinding a meaningful piece of Wednesday's historic gain. BioNTech, which had climbed 21.96% to $113.12 on someone else's trial result, fell 4%. The iShares Biotechnology ETF dropped 2% to $213.64 against the Nasdaq's 0.5% decline, with Moderna sitting inside it as a holding.

That was the classic buy-the-rumour, sell-the-news unwind, and it was concentrated in the mRNA developers rather than the infrastructure names.

The distinction is the whole argument for owning a genomics fund over an mRNA basket. Moderna posted a second-quarter net loss of $782 million, continues burning operating cash, and carries negative EPS projections through at least fiscal 2028. The rally was sentiment; the fundamentals have not caught up. The revenue from a therapy approved in the first half of 2027 is years away.

Tempus AI, by contrast, just delivered its first quarterly profit on $382.5 million of revenue growing 22%, and raised full-year guidance to $1.6 billion.

Friday saw the complex firm again. Moderna rose 13.20% to $150.91 and traded as high as $155.60, up 16.71%, as the market split the difference between Wednesday's euphoria and Thursday's reversal.

The two-day round trip on the headline name — up 177%, down 22%, up 13% — is a volatility profile that will show up in ARKG's daily prints for weeks. The fund's holdings are smaller, less liquid and more sensitive to sentiment than large-cap pharmaceuticals.

What Thursday established is that the sector-wide repricing held even as the trigger name gave back a fifth of its gain. Biotech ETFs did not surrender their record closes.

That is the evidence for a re-rating rather than a spike.

Up 90% In A Year And 64% Year-To-Date

The performance history explains why this move feels different to anyone who has held the fund.

ARKG has returned 90.00% over the past twelve months including distributions and is up roughly 64% year-to-date in 2026. Comparable one-year figures put it at 97% against 92% for XBI and 83% for IDNA.

Against that, the longer record is punishing. Since inception on October 31, 2014, the average annual return is 8.26%. As of May 1, 2026, the trailing three-year average annual return was 1.6% and the five-year average was negative 18.8%.

A fund that compounds at negative 18.8% for five years and then returns 90% in one has not created wealth. It has partially recovered a drawdown.

The price path tells it plainly. ARKG traded $20.95 on May 30, 2025 within a 52-week range of $17.51 to $31.16. Through August 2025 it sat between $23.36 and $23.72. On May 1, 2026 it closed at $30.30. On August 19, 2026 it closed at $47.67.

From $17.51 to $47.67 is a 172% recovery. From the early-2021 peak, the fund remains far below where it traded when assets reached $9 billion.

The year-to-date sector context is useful. As of mid-June, ARKG was up about 20% for the year against 17.9% for XBI, 14.5% for IDNA, 11.6% for the Virtus clinical trials fund and 10% for Global X Genomics. By August 19 ARKG's figure had reached 64%.

That acceleration — from 20% in June to 64% in August — came almost entirely in the last eight weeks and disproportionately in the last three sessions.

XBI has surged 34% since March and 61% to 77% over twelve months depending on measurement date, outperforming both broad healthcare and the S&P 500 by wide margins.

The rotation into innovative drugmakers is real and it predates Wednesday. The trial result accelerated something already underway.

The AUM Story: $9 Billion To $1.57 Billion And Back

The asset base is the structural variable that determines whether this fund can capitalize on its own performance.

ARKG's assets under management peaked near $9 billion in early 2021 during the pandemic-era innovation boom. By early 2026 they had fallen to approximately $1.2 billion. On May 1, 2026 the figure stood at $1.04 billion. By July 24 it had recovered to $1.57 billion.

That $1.57 billion was measured before the fund appreciated another 28% and before Wednesday's record session. Assets have grown materially since.

The decline from $9 billion created a genuine operational problem. As the fund shrinks, ARK may be forced to sell smaller-capitalization holdings with limited liquidity — potentially moving market prices against itself in the process. A concentrated portfolio of 33 names, many of them small-cap biotech, cannot be liquidated quickly without impact.

That mechanic works in reverse during inflows. New money must be deployed into the same illiquid names, which pushes prices up and improves reported performance, which attracts more money. Concentrated active funds in recovering sectors produce reflexive returns in both directions.

The current phase is the favourable one. Assets rising into a sector at record highs means the fund is buying into strength with fresh capital.

The vulnerability is that the same reflexivity operates on the way down, and this fund has demonstrated it: a five-year average annual return of negative 18.8% is what the unwind from $9 billion looked like.

Morningstar assigns ARKG a quantitatively derived Negative Medalist Rating, rated June 30 and published July 28, indicating the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

That rating was assigned before this quarter's returns and reflects the long-run record rather than the recent one.

Aggregate ratings elsewhere read Moderate Buy, and the technical signal set based on moving averages reads Strong Buy.

Those two assessments are measuring different things.

The 0.75% Problem

The fee is the one durable disadvantage this product carries and it has not moved in a decade.

ARKG charges a net expense ratio of 0.75% with no fee waiver. Peer averages sit at 0.73% for theme ETFs, 0.72% for equity ETFs and 0.69% for exchange-listed funds broadly — but those peers apply substantial waivers, bringing net expenses to 0.60% to 0.65%.

ARKG's headline and net figures are identical because there is nothing to waive.

Against a passive genomics alternative, the gap is wider still. The iShares Genomics Immunology and Healthcare ETF launched in June 2019 as an index-tracking product at a fraction of the cost.

The active management premium has to be earned in returns, and over the full holding period it has not been. An 8.26% average annual return since 2014 against a 0.75% annual drag means fees consumed roughly 9% of the gross return every year.

Over the past twelve months, active selection did earn it. ARKG's 97% one-year return against IDNA's 83% is 14 percentage points of outperformance for 50-odd basis points of additional cost.

The structural difference explains why. IDNA's holdings are dominated by major pharmaceutical firms — Moderna, Regeneron, Gilead — while ARKG tilts toward significantly smaller companies. That tilt cost the fund enormously during the 2021 to 2025 unwind and is paying now.

Any actively managed product is ultimately a bet on the portfolio managers who pick the stocks. That statement is more literally true here than for almost any other exchange-traded fund, given 33 positions and 61% concentration in the top ten.

The daily transparency is a mitigating feature. ARK publishes trade disclosures every day, which means anyone holding the fund can see exactly what changed and when — a level of visibility no other active manager provides.

The dividend history is irrelevant. The fund yields 0.00% and has made five distributions in its life, the most recent listed for December 2021.

This is a total return vehicle or it is nothing.

IDNA Beat It On The Day And That Is Not An Accident

The relative performance on Wednesday is informative about what each fund actually is.

The iShares Genomics Immunology and Healthcare ETF gained 13% for its best day on record. ARKG gained 10% for its strongest session in more than a year. XBI gained between 4.3% and 5.90% for its best day in nearly five months. IBB added 5.3% to 6.58%.

IDNA won because it holds Moderna directly. Its portfolio is weighted toward large pharmaceutical names, and the stock that moved 177% is inside it.

ARKG does not own Moderna. Its 10% came from the second-order beneficiaries — Tempus AI at 23.91%, plus sympathy moves across the sequencing and diagnostics complex.

Over twelve months the ranking inverts: ARKG at 97%, XBI at 92%, IDNA at 83%. Moderna itself is up nearly 525% over the same period, which means IDNA's large-cap weighting diluted the single best performer in the sector.

The structural differences across the four vehicles are worth holding. XBI uses a modified equal-weight structure across 155 holdings, which gives direct exposure to a broad biotech re-rating without single-name concentration. IBB holds 247 companies weighted by capitalization. IDNA tracks an index. ARKG picks 33 names actively.

For anyone positioning on the precision-medicine narrative specifically, IDNA and ARKG are the targeted expressions while XBI and IBB offer broader exposure to a biotech revival.

ARKG is the most aggressive version of that trade.

The trade-off is symmetrical. Higher concentration produced 97% over twelve months and negative 18.8% annualized over five years. The same portfolio construction generated both numbers.

Whoever owns this fund is expressing a view on genomics specifically and on ARK's stock selection within it — not on healthcare, and not on biotech broadly.

Read-Across: Eight More Trials Into 2027

The reason this repricing has legs beyond a single session is what comes next on the calendar.

The share price reaction indicates the market is pricing a read-across to at least eight other Phase 2 and Phase 3 trials of the same vaccine across a range of cancers — including renal cell carcinoma, bladder cancer, non-small cell lung cancer and metastatic melanoma. Results are expected in late 2026 and 2027.

Each of those readouts is a discrete catalyst for the entire genomics infrastructure complex, not just for the developer. If the mechanism generalizes across tumor types, the sequencing, synthesis and diagnostics volumes required scale with it.

The probability revisions already reflect that. One firm moved melanoma approval odds to 100% from 60% and lung cancer to 60% from 40%, expecting submission-to-approval within the first half of 2027.

The competitive field is broadening rather than consolidating. BioNTech is developing autogene cevumeran, a nearly identical therapy pairing custom mRNA with patient-specific tumor mutations, with 14 oncology trials in progress. That company rode a 22% gain on someone else's data specifically because the mechanism was validated.

More competitors pursuing personalized neoantigen therapies means more demand for the tooling layer, which is where ARKG's capital sits.

The broader catalyst environment has been dense. The FDA approved Regeneron's garetosmab for fibrodysplasia ossificans progressiva on August 19. Ultragenyx secured its first gene therapy approval. Illumina — the sequencing company underneath every personalized vaccine — rose 8.87% to $205 on the news.

CRISPR Therapeutics, at 6.17% of ARKG, has data readouts for CTX611 and CTX310 due in the second half of 2026, having already commercialized Casgevy with Vertex for two rare blood disorders.

That gives the fund a pipeline of position-specific catalysts independent of the mRNA story.

The counterweight: biotech has reached its highest level since the pandemic peak, and the market is now pricing successful outcomes across a set of trials that have not read out.

Technicals: $47.70 Is The Ceiling And There Is Nothing Above It

The chart on this fund is unusually simple because it just made a record.

ARKG closed August 19 at $47.67 after touching $47.70 intraday. That high is the top of the 52-week range, and the fund has never traded above it. There is no overhead supply, no trapped holders selling into strength, and no prior resistance to work through.

The bottom of the range at $23.43 is 50.9% below the current price.

The technical signal set based on moving averages and other indicators reads Strong Buy. That is what happens when a fund gaps 10% to an all-time high — every moving average sits beneath price by construction.

The gap itself is the near-term vulnerability. A 10.32% single-session move from $43.21 to $47.67 leaves an unfilled area on the chart, and gaps of that magnitude get retested more often than not. The $43.21 previous close is the obvious magnet.

The intraday low at $45.17 is the first reference beneath current levels and represents where buying emerged during the record session.

The comparison points across the complex all made records the same day: XBI, IBB, IDNA, XLV and the Nasdaq Biotechnology Index. When an entire sector prints all-time highs simultaneously, the subsequent consolidation is usually shallow and sideways rather than a full retrace — the marginal seller has no better place to rotate to.

The momentum profile has been building for months rather than days. XBI's 200-day moving average has been rising, and the sector cleared its early-2021 record weekly level this week — a ceiling that had held for five and a half years.

That breakout is the structural event. A sector reclaiming a five-year high after a 60% drawdown is a different setup from a sector spiking on news.

For ARKG specifically, the fund's own early-2021 peak came when assets were near $9 billion. Price and assets have both recovered substantially, and the price is now at a record while assets are not.

That divergence means the fund is worth more per share than at the AUM peak, with a smaller and more concentrated portfolio behind it.

The Levels: $47.70 Overhead, $43.21 And $23.43 Underneath

Immediate resistance. $47.70 is the all-time high and the top of the 52-week range. Above it there is no chart history — the fund is in price discovery on any close above that level.

Above that. Round-number references at $50 and $55 become the working targets. Extending to the fund's early-2021 territory would require substantially more, and the exact level depends on the distribution-adjusted series rather than the raw price.

First support. $47.60 was the after-hours print and $45.17 the intraday low on the record session. That $45 area is the first genuine shelf.

Second support. $43.21 is the previous close before the gap and the most likely target on any mean reversion. Filling that gap would be a 9.4% decline from $47.67 and would not damage the structure.

Third support. The $36 to $38 area, where the fund traded through July while assets stood at $1.57 billion, is the pre-breakout base.

Deeper. $30.30 marks the May 1 close. Below that, the $23.43 low is 50.9% away and would require the entire biotech re-rating to unwind.

The framing into September: above $45 the structure is intact and $47.70 is the gate to price discovery. Between $43.21 and $45 is gap-fill consolidation. Below $43.21 the record session is fully retraced.

The complication with mapping levels on this fund is that it does not have its own price discovery. It is a 33-position portfolio, and 61% of its value sits in ten names. A single holding moving 24% — as Tempus did — shifts the fund 1.7 percentage points regardless of what any moving average says.

The correct way to trade it is to track the holdings, not the chart. Tempus reports again with the Personalis integration underway. CRISPR has CTX611 and CTX310 readouts in the second half. Illumina sits underneath the whole sequencing thesis without being in the fund.

The daily trade disclosures from ARK are the only genuine edge available here, and they are free.

What Could Break It

The honest bear case has four components and none of them require the science to fail.

The commercial gap. A successful Phase 3 is not a product. Detailed clinical data, regulatory review, manufacturing economics and results across additional tumor types all still matter. The therapy's earliest plausible approval sits in the first half of 2027, and revenue follows after that. Every stock in this complex has repriced on a probability shift, not on cash flow.

The valuation already embedded. One firm has flagged that Moderna's price reflects more than $20 billion in risk-adjusted peak sales for this single therapy — approaching Keytruda's scale on an unadjusted basis. If the sector's anchor name is priced for perfection, the second-order names are priced off it.

Rates. The 30-year Treasury sits at 5.25% and the 10-year near 4.70%. Biotech is the longest-duration equity asset class in the market — companies with no earnings and cash flows a decade out. Every basis point of long-end yield compresses those valuations directly. The sector rallied this week despite yields, not because of them, and a hawkish Jackson Hole keynote on August 28 lands into a complex at record highs.

Concentration and liquidity. Thirty-three positions with 61% in the top ten, many of them small-capitalization names with limited trading depth. The fund's asset decline from $9 billion to $1.2 billion demonstrated what forced selling into illiquid holdings does to reported performance. That mechanic has not been repealed; it is simply running in the favourable direction.

The fifth risk is the sector's own history. Biotech has just reached its highest level since the pandemic peak, and the last time it got there the subsequent five years produced a negative 18.8% annualized return for this fund.

Seasonal pullbacks are the base expectation after a move of this speed.

The offsetting structural point: the current rally is being driven by clinical results and M&A rather than by liquidity and retail speculation, which was the 2021 driver. Under-20x earnings multiples across parts of the complex and a rising 200-day average describe a different setup.

ARKG ETF Price Forecast: Base, Bull And Bear Into Q4

Base case. ARKG consolidates between $43.21 and $47.70 through September while the gap from the record session partially fills. This is the highest-probability path. A 10.32% single-day move to an all-time high on a clinical headline invites profit-taking, and Moderna's 22.10% Thursday reversal showed the trigger name cannot hold a straight line. The sector-wide record closes across XBI, IBB, IDNA and XLV held through that reversal, which argues for shallow consolidation rather than a full retrace. Watch the daily close against $45 as the cleanest read on control.

Bull case. A close above $47.70 puts the fund into price discovery with $50 and then $55 as the working targets. That path needs three things: continued positive readouts from the eight other Phase 2 and 3 trials of the same therapy across renal, bladder and lung cancers into late 2026 and 2027; Tempus AI executing the Personalis integration while holding the $1.6 billion revenue guide and its newly achieved profitability; and long-end Treasury yields stabilizing or falling from 5.25%. Add CRISPR's CTX611 and CTX310 readouts landing positively in the second half and the fund's 33-name portfolio has a dense catalyst calendar into year-end. Asset growth from $1.57 billion adds a reflexive tailwind as new capital buys illiquid holdings.

Bear case. A close below $43.21 fully retraces the record session and puts the pre-breakout base at $36 to $38 in play. The triggers are specific: a hawkish Jackson Hole keynote on August 28 sending the 30-year above 5.35% and compressing long-duration valuations, a disappointing readout from any of the follow-on trials, or manufacturing economics for personalized therapies proving worse than modelled. Below $36, the $30.30 May level and eventually the $23.43 low come into range — though that would require the entire biotech re-rating to unwind.

What actually decides it. Three variables, in order. Tempus AI, because a 7.09% position that moves 24% in a session is the largest single determinant of this fund's daily return and it now carries execution risk on a $1.5 billion acquisition. The follow-on trial calendar, because the market has priced a read-across to eight studies that have not reported. And the long end of the Treasury curve, because a portfolio of pre-revenue biotechnology companies is the purest duration bet available in equities.

At $47.67 the fund has priced a mechanism validation. It has not priced a commercial product, and that gap is measured in years.

That's TradingNEWS